PRIMAQUINE DIPHOSPHATE

Primaquine diphosphate is an 8‑aminoquinoline antimalarial active against hepatic hypnozoites and gametocytes. It is used for radical cure of Plasmodium vivax and P. ovale and to reduce transmission. Side effects include GI upset, methemoglobinemia, and hemolytic anemia in G6PD‑deficient patients, so screening is essential.

SKU: 92295f1fe816 Category: Tag:

Product Description


Mechanism of Action

PRIMAQUINE DIPHOSPHATE (ID 27229) exhibits a complex, multi‑pathway biochemical activity profile influencing enzymatic cascades, receptor‑mediated signalling networks, mitochondrial respiration, oxidative‑stress balance, intracellular ion regulation, membrane‑potential stability and transcription‑factor activation. Its structural framework suggests potential interactions with catalytic residues, allosteric regulatory pockets, membrane‑embedded receptor complexes and intracellular signalling scaffolds. These interactions may modulate phosphorylation patterns, second‑messenger systems (Ca²⁺, IP₃, DAG, cAMP), ATP turnover, ROS equilibrium, cytoskeletal organisation and organelle stress‑response thresholds.

Depending on dosing, PRIMAQUINE DIPHOSPHATE can influence metabolic flux routing, alter chromatin accessibility, modify vesicular transport, reshape mitochondrial output and regulate transcriptional clusters associated with cellular survival, apoptosis, autophagy, inflammatory signalling and metabolic adaptation. This multi‑axis behaviour supports its wide applicability in advanced biochemical and pharmacodynamic research systems.

Benefits and Advantages

The compound is widely utilised for:

  • Receptor–ligand interaction analysis and affinity modelling
  • Enzyme‑kinetic profiling and catalytic‑pathway reconstruction
  • Mitochondrial‑bioenergetics assays and oxidative‑stress evaluation
  • Multi‑omics integration (transcriptomics, proteomics, metabolomics, phosphoproteomics)
  • Cytoskeletal and membrane‑dynamics studies
  • Apoptosis, necroptosis, autophagy and ferroptosis pathway characterisation
  • SAR (structure–activity relationship) development and molecular screening
  • Pharmacodynamic modelling and mechanistic dose–response simulations

Side Effects and Risks

Potential laboratory‑observed risks include:

  • Excessive ROS production and oxidative imbalance
  • Mitochondrial hyperactivation or suppression of electron‑transport complexes
  • Ion‑channel dysregulation (Na⁺, K⁺, Ca²⁺)
  • Unintended receptor cross‑talk or inhibition
  • Cytoskeletal destabilisation and membrane‑integrity compromise
  • Dose‑dependent cytotoxicity or activation of apoptotic/autophagic pathways
  • Transcriptional or epigenetic instability
  • Upregulation of inflammatory cascades (NF‑κB, JNK, p38 MAPK)

Use exclusively within controlled laboratory conditions and according to strict biosafety standards.

Datasheet


Molecular Formula

C15H27N3O9P2

Molecular Weight

455.34 g/mol

CAS Number

63-45-6

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

5.64e-02 g/L

Purity

Purity information is available upon request (COA).

Synonym

primaquine diphosphate; 63-45-6; PRIMAQUINE PHOSPHATE; Malquine; 1,4-Pentanediamine, N4-(6-methoxy-8-quinolinyl)-, phosphate (1:2)

IUPAC/Chemical Name

4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine;phosphoric acid

InChl Key

GJOHLWZHWQUKAU-UHFFFAOYSA-N

InChl Code

InChI=1S/C15H21N3O.2H3O4P/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14;2*1-5(2,3)4/h4,6,8-11,18H,3,5,7,16H2,1-2H3;2*(H3,1,2,3,4)

References

https://pubchem.ncbi.nlm.nih.gov/compound/6135;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download